ADDF awards grant to aid initiation of AGB101 Phase 3 trial for aMCI treatment The Alzheimer&39.

AgeneBio expects to initiate the AGB101 Phase 3 clinical system in the second fifty % of 2015. Related StoriesStudy discovers high prevalence of dehydration in older people living in UK treatment homesHealth Education England launches Dementia Core Skills Education and Training FrameworkResearchers find that stem cell treatment may reduce cognitive impairment related to dementia with Lewy bodiesAGB101 may be the first and only treatment to target hippocampal hyperactivity, a condition characteristic of the aMCI stage of Alzheimer's disease.Its mission is to further the understanding, medical diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting analysis, clinical care, education, training, and advocacy in hematology. ASH provides Bloodstream: The Vital Connection ( a credible online resource addressing bleeding and clotting disorders, anemia, and cancers. The state journal of ASH is certainly Bloodstream ( the most cited peer-reviewed publication in the field, which comes in print and online weekly.

The 340B Plan mega-guidance recently released by the Health Resources Services Administration sets stricter standards for contract pharmacy use.